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Summary 20 
 In addition to removing organics and other nutrients, the microorganisms in wastewater 21 
treatment plants (WWTPs) biotransform many pharmaceuticals present in wastewater. The 22 
objective of this study was to examine the relationship between pharmaceutical 23 
biotransformation and biodiversity in WWTP bioreactor microbial communities and identify taxa 24 
and functional genes that were strongly associated with biotransformation. Dilution-to-extinction 25 Au
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of an activated sludge microbial community was performed to establish cultures with a gradient 26 
of microbial biodiversity. Batch experiments were performed using the dilution cultures to 27 
determine biotransformation extents of several environmentally relevant pharmaceuticals. With 28 
this approach, because the communities were all established from the same original community, 29 
and using sequencing of the 16S rRNA and metatranscriptome, we identified candidate taxa and 30 
genes whose activity and transcript abundances associated with the extent of individual 31 
pharmaceutical biotransformation and were lost across the biodiversity gradient. Metabolic genes 32 
such as dehydrogenases, amidases, and monooxygenases were significantly associated with 33 
pharmaceutical biotransformation, and five genera were identified whose activity significantly 34 
associated with pharmaceutical biotransformation. Understanding how biotransformation relates 35 
to biodiversity will inform the design of biological WWTPs for enhanced removal of chemicals 36 
that negatively impact environmental health.  37 
 38 
Introduction 39 
Wastewater treatment plants (WWTPs) harness microbes to treat human waste and 40 
protect our environment from organic pollutants, nutrients, and pathogens. In addition to 41 
conventional pollutants, however, thousands of pharmaceuticals are excreted by humans in intact 42 
and metabolized forms, reaching WWTPs before being released into the environment (Kolpin et 43 
al., 2002). The ability of the microbes in WWTPs to biotransform these chemicals is an area of 44 
great interest (Carballa et al., 2004; Castiglioni et al., 2005; Nakada et al., 2006; Kasprzyk-45 
Hordern et al., 2009). Substantial research has advanced our knowledge of pharmaceutical 46 
biotransformation pathways (Ellis et al., 2006) and the transformation products formed during 47 
treatment (Kern et al., 2010). However, only one study to our knowledge has linked chemical 48 
transformation data with wastewater microbial community composition and activity (Helbling et 49 
al., 2015), and no studies to date have identified specific functions associated with 50 
biotransformation to develop predictive relationships between functional characteristics of the 51 
microbial community and pharmaceutical biotransformation pathways and extents.  52 
Biodiversity is one characteristic of wastewater treatment microbial communities that 53 
may impact pharmaceutical biotransformation rates (Johnson et al., 2015). WWTPs harbor 54 
extremely diverse microbial communities (Zhang et al., 2011). Mounting evidence from studies 55 
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of microbial systems suggests a positive relationship between biodiversity and the rates and/or 56 
magnitude of community functions (reviewed by Cardinale et al., 2006; Duffy, 2008). Functional 57 
redundancy, the concept that taxonomically distinct species have the same ecological function, 58 
challenges the idea that changes in biodiversity will directly affect community process rates. This 59 
is because processes that are carried out by many taxonomically distinct microorganisms, or 60 
broad processes, would not necessarily be impacted by biodiversity losses as the process rate is 61 
not limited by the number of species that can perform it. Conversely, narrow processes, or 62 
processes performed by few species, would be positively correlated with biodiversity because the 63 
process rate is limited by the number of species able to perform the specialized metabolism.  64 
In wastewater systems, biodegradation processes may be broad or narrow depending on 65 
the compound under consideration. Given the diverse chemical structures of pharmaceuticals, 66 
their biotransformation could be catalyzed by either broad or narrow processes. In a study of 67 
microbial communities from ten full-scale treatment systems, a positive association between 68 
taxonomic and functional biodiversity and the rates of some compounds was observed (Johnson 69 
et al., 2015). However, not all compound biotransformation rates in this study exhibited a 70 
positive association with biodiversity; those compounds were likely transformed by broad 71 
processes. In laboratory-manipulated bioreactors, Pholchan et al. (2013) found that communities 72 
with greater diversity were associated with a decrease in the removal of a suite of estrogens (17-73 
estradiol (E2), estrone (E1), estriol (E3), and 17α-ethinylestradiol (EE2)), which was 74 
counterintuitive to their hypothesis. They concluded that it was not possible to make blanket 75 
statements about the relationship between rare functions and biodiversity. Conversely, 76 
Hernandez-Raquet et al. (2013) found that dilution-induced reduction in diversity of an activated 77 
sludge community resulted in significant reductions in phenanthrene mineralization. These 78 
studies collectively show that while positive biodiversity-function relationships may hold for 79 
specific pharmaceutical biotransformations and collective pharmaceutical biotransformation, 80 
more resolved information, such as the relative activity of specific taxa and/or functions, is 81 
needed to understand conflicting patterns observed for individual pharmaceutical compounds. 82 
Understanding whether pharmaceutical biotransformations are catalyzed by highly redundant 83 
populations, or performed by rare taxa can help us identify the enzymes that catalyze their 84 
transformation and exploit opportunities for enhancing biotransformations during wastewater 85 
treatment. 86 
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 The goal of this study was to elucidate a more resolved understanding of why and how 87 
biodiversity affects pharmaceutical biotransformation by experimentally manipulating the 88 
biodiversity of wastewater microbial communities. We manipulated an activated sludge 89 
community using a dilution-to-extinction approach to create communities with different levels of 90 
biodiversity and directly test the relationship between biodiversity and function (here, defined as 91 
pharmaceutical biotransformation). With this approach, because the communities were all 92 
established from the same original community, we hypothesized that we could identify taxa and 93 
differentially expressed genes that were correlated with pharmaceutical biotransformation. These 94 
taxa and genes can serve as predictive biomarkers for pharmaceutical biotransformation and 95 
WWTPs could be designed or operated to enhance the activity of these taxa and functions to 96 
improve overall pharmaceutical biotransformation by wastewater microbial communities. 97 
Results 98 
Dilution resulted in communities with different levels of biodiversity 99 
A gradient in microbial biodiversity in an activated sludge community was established 100 
using a dilution-to-extinction approach (Szabó et al., 2007; Peter et al., 2010; Philippot et al., 101 
2013; Ylla et al., 2013). In this approach, each dilution theoretically removes the least abundant 102 
species from the previous culture, resulting in a less diverse subset of the original community. 103 
Activated sludge was serially diluted stepwise (1:10) in sterile semi-synthetic sewage media 104 
(SSM) to achieve dilution conditions from 10-1 to 10-7. After serial dilution, triplicate flasks of 105 
the 10-2, 10-4, and 10-7 dilutions were allowed to regrow overnight such that all the dilution 106 
cultures were a similar abundance. After regrowth, the biomass was pelleted and resuspended in 107 
fresh SSM before performing the pharmaceutical biotransformation batch experiments. We 108 
quantified the loss of seven pharmaceuticals and normalized the loss of each compound by the 109 
biomass concentration and time elapsed between initial and final sample collection for each 110 
batch. Biomass samples were collected from each batch for DNA and RNA extractions and 111 
sequencing. The 16S rRNA gene and 16S rRNA sequencing data were used to calculate the 112 
DNA- and RNA-based taxonomic biodiversity measurements, respectively, and the shotgun 113 
metagenomic and metatranscriptomic sequencing data were used to generate the DNA- and 114 
RNA-based functional biodiversity measurements, respectively. 115 
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With increased dilution, there was a decrease in the taxonomic richness of the activated 116 
sludge microbial community based on both 16S rRNA gene and 16S rRNA sequencing 117 
(ANOVA, P<0.05). Rarefaction curves of unique operational taxonomic units (OTUs; grouped 118 
based on sequence similarity of greater or equal to 97%) based on both DNA and RNA versus 119 
sequences sampled show distinct clustering of the dilution cultures, with samples from the most 120 
diverse culture (10-2) having the greatest number of unique OTUs, followed by the medium-121 
biodiversity culture (10-4), and the low-biodiversity culture (10-7
We did not observe significant differences in DNA-based functional richness between the 126 
dilution conditions (Figure 1B, Table 1; t test, Bonferroni-adjusted two-sided P>0.05), in 127 
contrast to the DNA-based taxonomic richness measurements. Conversely, RNA-based 128 
functional richness (Figure 1D) was significantly different between each dilution condition based 129 
on pairwise comparisons (t test, Bonferroni-adjusted two-sided P<0.05). Overall, differences in 130 
biodiversity measurements were not consistent between DNA and RNA-based approaches, or 131 
between taxonomic and functional datasets.  132 
) that plateaued with the lowest 122 
number of unique OTUs (Figure 1A and 1C). Differences in DNA-based taxonomic diversity 123 
between the dilution cultures are supported by various biodiversity indices based on the 16S 124 
rRNA gene sequence data (Table 1).  125 
Taxonomic and functional diversity positively associated with one another 133 
 To understand if more unique taxa corresponded to increased functional traits in the 134 
wastewater microbial communities, we first tested whether taxonomic richness was positively 135 
associated with functional richness. We found that for both the DNA- and RNA-based 136 
annotations, there was a significant positive association between taxonomic and functional 137 
richness (Figure S2; Spearman, P<0.005). The shape of the data in Figure S2 suggests that the 138 
number of unique functions does not increase linearly with the number of unique OTUs and 139 
instead the number of functions levels out at high numbers of OTUs. This is consistent with the 140 
idea that the most diverse communities are also the most functionally redundant and that the 141 
unique OTUs contain many of the same functional genes.   142 
Carbon oxidation and pharmaceutical transformations show different patterns with dilution 143 
 Carbon utilization, a process that is widespread across all forms of life, is a function that 144 
we expected to be functionally redundant across all the dilution conditions. Thus, we 145 
Figure 1 
Table 1 
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hypothesized that there would not be a significant difference in specific carbon oxidation rates 146 
between the dilution conditions. To test this, dissolved organic carbon was measured in samples 147 
across the experiment to determine carbon oxidation rates (Figure S3). Indeed, we found no 148 
significant difference between volatile suspended solids (VSS)-normalized carbon oxidation 149 
rates across all dilution conditions (ANOVA, P>0.64). In all dilution conditions we found no 150 
significant association between specific carbon oxidation rate and taxonomic or functional 151 
richness (Spearman, P >0.80), supporting the notion that carbon oxidation is a function that is 152 
widespread and redundant in wastewater microbial communities (Franklin and Mills, 2006). 153 
In contrast to specific carbon oxidation rate patterns, significant differences between the 154 
degree of biotransformation and the dilution condition were observed for 5 of the 7 155 
pharmaceutical compounds, with greater extents of biotransformation observed in the most 156 
diverse culture (ANOVA, P<0.05; Figure 2).  Two compounds did not follow the same pattern as 157 
the rest: for glyburide, no significant differences in extent of biotransformation between the 158 
dilution cultures were observed as very limited loss of the parent compound occurred; and for 159 
erythromycin, the greatest loss was observed in the 10-4 condition, though it was not statistically 160 
significantly different from the 10-2 condition (t test, Bonferroni adjusted P>0.05).  Atenolol was 161 
the only compound for which the stepwise dilution resulted in a corresponding stepwise 162 
reduction in biotransformation. For the other compounds, there was only a significant difference 163 
in biotransformation extent between the 10-2
Significant associations between functional richness and pharmaceutical biotransformation 165 
extent were observed 166 
 and the other dilution conditions. 164 
 We observed a significant positive association between DNA- and RNA-based functional 167 
richness measurements and scaled pharmaceutical biotransformation extents (Spearman, P<0.05; 168 
Figure 3). Notably, RNA-based functional richness was a better predictor of pharmaceutical 169 
biotransformation extent than DNA-based functional richness based on Spearman rank 170 
correlation coefficient values (ρRNA-func-richness = 0.93, ρDNA-func-richness 
Figure 2 
= 0.77). This indicates that 171 
expressed genes are better predictors of pharmaceutical biotransformation and supports the 172 
notion that metagenomic datasets may mask significant associations with magnitudes of 173 
community functions as they include non-expressed traits. The observed functional richness 174 
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appears to plateau (Figure 3A), particularly between the 10-2 and 10-4 
Differential expression of functional genes suggests potential enzymes associated with 181 
biodegradation 182 
conditions, whereas the 175 
observed taxonomic richness does not (Figure 3B), again indicative of a large degree of 176 
functional redundancy in the most diverse microbial communities. We chose to focus on RNA-177 
based taxonomic and functional richness when assessing associations with pharmaceutical 178 
biotransformation and to identify lost active OTUs and expressed functional genes across the 179 
dilution conditions. 180 
After observing that there were significant positive associations between biodiversity and 183 
pharmaceutical biotransformation extent, we asked which functions were differentially expressed 184 
across the dilution cultures, and specifically which functions were lost? Of the 710,402 genes 185 
with predicted functions analyzed from the combined assembly, 15,290 were found to be 186 
differentially expressed between the three dilution conditions (Benjamini-Hochberg adjusted 187 
P<0.05) and to have matches in the KEGG Orthology database. Differential expression could 188 
have been due to differences in transcript abundances, or to gene absence in the different dilution 189 
conditions. The majority of the significantly differentially expressed functions were lost with 190 
dilution from the 10-2 to the 10-7 cultures (negative log fold change, Figure S6). For the 191 
compounds that were transformed to different extents across the three dilution conditions, the 192 
genes that had a lower level of expression in the least diverse culture (10-7
We sought to establish whether genes that might have been involved in pharmaceutical 195 
biotransformation were differentially expressed across the dilution conditions and thus focused 196 
on compounds that were transformed to a different extent with increased dilution (atenolol, 17α-197 
ethinylestradiol (EE2), trimethoprim, venlafaxine, erythromycin, and carbamazepine). For all 198 
compounds except erythromycin, we further narrowed the list of genes relevant to those 199 
compounds by selecting genes only if they were lost with increased dilution. The list of genes 200 
was narrowed by focusing on classes of metabolic genes that were predicted to be involved in the 201 
compound’s biotransformation by the EAWAG-BBD Pathway Prediction System (Ellis et al., 202 
2006; EAWAG, 2016). The classes of metabolic genes included were those with functional 203 
assignments for genes which transcribe the following enzymes:  amidase, nitrilase, transaminase, 204 
) could be responsible 193 
for pharmaceutical biotransformation.  194 
Figure 3 
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demethylase, oxidase, hydrolase, dehydrogenase, aminotransferase, monooxygenase, 205 
hydroxylases, esterase, lactonase, amidohydrolase, dioxygenase, oxygenase, lactamase, sulfatase, 206 
and dimethylaminehydrogenase.  Spearman rank correlation tests between the normalized 207 
expression of each of the genes that were predicted to be involved in biotransformation and each 208 
compound’s biotransformation extent was performed to identify genes with expression patterns 209 
that were significantly associated with biotransformation extent. The list of statistically 210 
significant genes for each compound is given in Table S6.    211 
 Gene set enrichment analysis was used to understand which KEGG functions were more 212 
likely to be positively or negatively associated with biotransformation across all the compounds 213 
analyzed. By comparing entire categories of functions, rather than individual genes, the 214 
statistical power of the analysis increases. This analysis also allowed us to evaluate which KEGG 215 
functional group categories were biomarkers for overall transformation (Table S7), rather than 216 
just statistically correlated with transformation of each individual compound. Based on a 217 
literature review, there is previous evidence for use of many of the associated genes as 218 
biomarkers for aromatic compound degradation. A heat map showing expression of genes 219 
annotated with to these KEGG categories across the different dilution conditions is shown in 220 
Figure S6.  221 
Active taxa, or operational taxonomic units (OTUs) that associated with biotransformation 222 
extent were identified  223 
 We identified specific OTUs that may have been involved in pharmaceutical 224 
biotransformation and were lost across the dilution conditions. Using the 16S rRNA sequencing 225 
results, we identified specific OTUs whose activity (abundance of 16S rRNA gene transcripts) 226 
significantly associated with individual and collective pharmaceutical biotransformation extents 227 
(Table 2). We narrowed the list of significantly associated OTUs to those that were relatively 228 
active in the 10-2 condition (using a cutoff of 0.5% average relative activity in the 10-2 condition). 229 
Five OTUs whose activity significantly associated with individual and/or collective 230 
pharmaceutical biotransformation extents were identified (Table 2). While this approach does not 231 
allow us to definitively conclude that these taxa are involved in biotransformation (e.g., they 232 
could simply co-occur with taxa that perform the biotransformation reactions), they can be 233 
viewed as a list of useful biomarkers that are predictive of biotransformation. Based on a 234 
literature review of the associated OTUs (references provided in Table 2), all have previously 235 
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been identified in biodegradation studies, either as directly involved in the biotransformation of a 236 
pollutant, or identified in systems performing aerobic pollutant degradation, thus supporting their 237 
potential importance in catalyzing pharmaceutical biotransformations.  238 
Discussion 239 
Despite a wealth of both pharmaceutical loss data across WWTPs and activated sludge 240 
sequencing data, we lack robust datasets that allow us to link the two sets of information. Further 241 
studies are needed to generate candidate lists of taxa that might be used as predictive biomarkers 242 
for pharmaceutical biotransformation so that we may be able to design and operate WWTPs to 243 
enhance biotransformation and address emerging water quality goals.  While a previous study 244 
looked at the relationship between biodiversity and pharmaceutical biotransformation in 245 
WWTPs, they did not go beyond testing associations with whole community biodiversity 246 
measurements. In order to gain a more mechanistic understanding of (1) why certain 247 
pharmaceuticals have strong positive associations with taxonomic and/or functional biodiversity; 248 
and (2) how microbial community structure and activity influences pharmaceutical 249 
biotransformation, we need to look at which specific functions and taxa are strongly associated 250 
with pharmaceutical loss. In this study, we go beyond bulk biodiversity measurements and 251 
identified both functional genes (Table S7) and OTUs (Table 2) whose activity significantly 252 
associated with pharmaceutical biotransformation. As the communities were all established from 253 
the same original community and diversity manipulations were achieved with a dilution-to-254 
extinction approach, we could examine how the loss of specific functions and taxonomic groups 255 
affected pharmaceutical biotransformation. Further, by comparing the relative activity of OTUs 256 
and gene across the dilution conditions, we identified OTUs and functional genes whose 257 
presence and expression correlated with biotransformation. The dataset generated in this study 258 
represents a resource for future studies that seek to link WWTP community structure and activity 259 
to pharmaceutical biotransformation. 260 
Taxonomic and functional richness associated with pharmaceutical biotransformation, and 261 
RNA-based richness had stronger associations than DNA-based richness measurements.    262 
We saw a strong positive association between both taxonomic and functional biodiversity 263 
and overall biotransformation extent (Figure 3), similar to the findings of Johnson et al. (2015). 264 
These results are also consistent with microbial communities studied in WWTPs and other 265 
Table 2 
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environments that showed that communities with more taxa are likely to have more functional 266 
traits (Gilbert et al., 2010; Bryant et al., 2012; Johnson et al., 2014). We also observed functional 267 
redundancy as the shape of the association between taxonomic and functional genes was not 268 
linear (Figure S2), and thus the most diverse communities likely had significant redundancy with 269 
respect to functional genes. We chose to use RNA-based functional and taxonomic richness 270 
measurements for testing associations with pharmaceutical biotransformation as RNA excludes 271 
non-expressed traits and captures the active fraction of the community. We observed differences 272 
in biodiversity measurements between DNA- and RNA-based approaches; for example, RNA-273 
based functional richness was significantly different between the dilution conditions, but not 274 
significantly different based on DNA (Table 1). This indicated that our RNA-based could 275 
potentially capture more pronounced differences in expressed functions between the dilution 276 
conditions.  277 
We found that pharmaceutical biotransformation rates were significantly associated with 278 
both functional and taxonomic richness (Figure 3). This indicates that for the purpose of 279 
understanding the relationship between biodiversity and function, amplicon sequencing of the 280 
16S rRNA was a sufficient measure of biodiversity to test associations with process rates.  This 281 
may not hold true in highly functionally redundant microbial communities, where expressed 282 
taxonomic and functional diversity are not strongly associated with one another (e.g. Ylla et al., 283 
2013). Using 16S rRNA to test relationships with biodiversity is advantageous because amplicon 284 
sequencing is more affordable, less computationally intensive because it generates a fraction of 285 
the data, and has more developed reference databases compared with functional genes. However 286 
only by performing metagenomic and metatranscriptomic sequencing is it possible to test 287 
associations with specific genes and generate candidate gene lists that can be used to discover 288 
mechanistic links with biotransformation.  289 
The taxa and functional genes that associated with pharmaceutical biotransformation were 290 
consistent with previous research and form a basis for testing causal relationships.  291 
We identified five OTUs whose activity significantly associated with individual 292 
compound biotransformation extents (atenolol and/or venlafaxine, Table 2). All the OTUs have 293 
previously been identified in biodegradation processes. Helbling et al. (2015) also found a 294 
significant association between venlafaxine and the activity of Chryseobacterium, despite 295 
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differences in experimental design (fed vs. starved batch conditions) and using different WWTP 296 
biomass. This supports the validity of our approach and suggests that the OTUs identified may 297 
serve as useful biomarkers across a range of wastewater environments. Further, taxonomic 298 
diversity may underpin faster, more resilient, and more robust processes because the different 299 
microbial community members have different properties (e.g. substrate affinities, energy, and 300 
nutrient requirements, etc.). While many different organisms may express similar genes and are 301 
capable of biotransforming pharmaceuticals, specific groups of organisms may be larger 302 
contributors to overall transformation rates. For example, Khunjar et al. (2011) found that both 303 
ammonia oxidizing bacteria (AOB) and heterotrophs were capable of catalyzing the 304 
hydroxylation of EE2, likely using a monooxygenase enzyme, but AOB perform the process 305 
much more rapidly than heterotrophs. Thus, understanding “who” is performing the function 306 
may be more important than the expression of the relevant functional gene to understanding what 307 
controls a biotransformation rate. This may also explain why we saw a strong association 308 
between atenolol biotransformation and functional richness. Based on our knowledge of atenolol 309 
biotransformation in aerobic systems (hydrolysis of the primary amide, Table S2), we might 310 
expect that it would be a relatively broad process. However, if the rate of the primary amide 311 
hydrolysis differs highly between taxa, then the positive association between atenolol 312 
biotransformation and taxonomic biodiversity would hold, and in turn also be positively 313 
associated with functional richness because of the positive association between taxonomic and 314 
functional richness.Beyond taxonomic data, we can use metagenomic and metatranscriptomic 315 
sequencing to test associations between pharmaceutical biotransformation extent and gene 316 
activity and generate candidate gene lists (Table S6) that can be used to discover mechanistic 317 
links with biotransformation. In this study, associated genes were extensive, the number of 318 
associated KEGG orthologs ranged from 5-156, depending on the compound. Therefore, the data 319 
generated from these associations is intended to be hypothesis-generating and elucidate targets 320 
for further study. To focus these targets, we used gene set enrichment analysis to identify KEGG 321 
functional groups that were statistically associated with pharmaceutical transformations across 322 
all of the compounds that had loss of transformation at increased dilution (Table S7 and Figure 323 
S6). Twenty-eight of the 39 KEGG functional groups that were significantly associated with 324 
pharmaceutical transformation encoded for dehydrogenase enzymes. In addition, many of the 325 
significantly associated genes encoded functions that are part of central metabolic pathways such 326 
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as oxidative phosphorylation, amino acid metabolism, and the TCA cycle. These associations 327 
were likely significant because these KEGG categories represented those that associated with 328 
transformation of all the compounds. Genes catalyzing more specific initial transformations were 329 
associated with the transformation of individual compounds. For example, the gene encoding for 330 
subunit C of the ammonia monooxygenase gene was associated with EE2 biotransformation 331 
(Benjamini-Hochberg adjusted P=0.025, ρ=0.69, adjusted for multiple comparisons), as we 332 
would expect given our knowledge of the transformation pathway (Khunjar et al., 2011). In 333 
addition, genes encoding amidase enzymes were associated with atenolol transformation 334 
(Helbling et al., 2010) (Benjamini-Hochberg adjusted P<0.03, ρ>0.78). The consistency of these 335 
results with other previous studies provides some validity to our approach. While the direct 336 
involvement of the enzymes encoded by these genes was not validated experimentally, the 337 
dataset of significantly associated genes (Table S6) provides insight to potentially important 338 
functional genes in pharmaceutical biotransformation. After initial biotransformation reactions, 339 
pharmaceutical compounds are eventually broken down into central intermediates, which may 340 
explain the increased expression of genes that encode general metabolic pathway functions. This 341 
is consistent with previous studies that observed increased expression of genes in related to 342 
amino acid metabolism, TCA cycle, and oxidative phosphorylation in microbial processes 343 
degrading organic contaminants (Annweiler et al., 2000; Li et al., 2012).  344 
Enhancing biodiversity in wastewater treatment plants could enhance overall 345 
biotransformation of pharmaceuticals.  346 
For those compounds for which we saw no significant difference between loss and 347 
dilution condition (e.g. erythromycin), increased biodiversity is not likely a successful strategy 348 
for achieving enhanced removal. Interestingly, the biotransformations of most the compounds 349 
studied (5 of 7) were narrow processes, as their extent of loss decreased with increased dilution 350 
(Figure 2). One way to enhance the loss of compounds that undergo these narrow 351 
biotransformation processes may be to design WWTPs to support diverse microbial communities 352 
and harness specific low abundance community members. Recent studies suggest that certain 353 
WWTP operational parameters, such as solids retention time (Vuono et al., 2016), dissolved 354 
oxygen conditions (Stadler and Love, 2016), and concentration and composition of dissolved 355 
organic matter (Li et al., 2014) can all influence the degree of microbial biodiversity and the 356 
extent of micropollutant removal.  Further research is needed to understand the relative 357 
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importance of these operational parameters and environment conditions and others on WWTP 358 
microbial biodiversity and pharmaceutical biotransformation. 359 
In conclusion, we observed significant positive associations between biodiversity of 360 
WWTP microbial communities and pharmaceutical biotransformation. By linking gene 361 
expression and relative activity with individual pharmaceutical biotransformation extents, our 362 
work goes beyond testing associations between biodiversity measurements and pharmaceutical 363 
biotransformation to identify metabolic genes and OTUs which can be potentially used as 364 
biomarkers for biotransformation. Metabolic genes such as dehydrogenases, amidases, and 365 
monooxygenases were significantly associated with pharmaceutical biotransformation. Five 366 
genera were identified whose activity significantly associated with pharmaceutical 367 
biotransformation (Table 2) and previous studies support their potential involvement in 368 
catalyzing biotransformation. Further experimentation is needed to conclusively link those 369 
functions and taxa to biotransformation reactions. The strong positive association between 370 
biodiversity and pharmaceutical biotransformation extent has implications for the design and 371 
operation of WWTPs to increase pharmaceutical removal. Specifically, creating niche 372 
environments that support the growth of diverse microbial communities could result in better 373 
overall performance with respect to pharmaceutical removal. Understanding the factors that drive 374 
biodiversity and enhance the activity of key populations involved in biotransformation is needed 375 
to harness the benefits of biodiversity for wastewater treatment. 376 
Experimental Procedures 377 
Experimental design and biodiversity manipulation 378 
An 8 L grab sample of activated sludge mixed liquor was collected from the aeration 379 
basin of the Ann Arbor WWTP, a facility that performs nitrification and moderate biological 380 
phosphorus removal. Biodiversity manipulations were achieved using a dilution-to-extinction 381 
approach. Dilution-induced reductions in diversity has been used in numerous previous studies to 382 
understand structure-function relationships in mixed microbial communities (e.g. Franklin and 383 
Mills, 2006; Hernandez-Raquet et al., 2013; Philippot et al., 2013). Before serial dilution, 384 
disaggregation of macroflocs in the activated sludge sample was achieved by blending 385 
approximately 500 mL of mixed liquor in an industrial blender (Waring Commercial Blender, 386 
Model 516L31) at maximum speed for 10 minutes. After blending, stepwise dilutions (1:10) 387 
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were performed by transferring 100 mL into 900 mL of sterile semi-synthetic sewage media 388 
(SSM) to achieve dilution conditions from 10-1 to 10-7. The SSM was comprised of filtered (0.22 389 µm Stericup, Millipore, Darmstadt, Germany) and autoclaved primary effluent collected from 390 
the Ann Arbor WWTP (detailed in Section 1.1 of the Supporting Information). Chemical oxygen 391 
demand (COD) was determined in the filtered and sterilized primary effluent using Standard 392 
Methods (2005), and then supplemented with carbon (a mixture of peptone, meat extract, humic 393 
acid) and ammonium chloride to achieve a final concentration of 1,850 mg/L as COD and 30 394 
mg-N/L as ammonium. The COD concentration was selected in order to maintain “fed” 395 
conditions throughout a significant portion of the batch experiment. After serial dilution, 396 
triplicate flasks of 200 mL of the 10-2, 10-4, and 10-7
Pharmaceutical biotransformation batch experiments 402 
 dilutions were allowed to regrow 397 
(approximately 14 hours) in an incubator-shaker at 20°C. Regrowth was performed to allow each 398 
of the dilution cultures to reach a similar abundance and biomass was pelleted and resuspended 399 
in fresh SSM prior adding the pharmaceutical compounds and initiating the biotransformation 400 
batch experiments. 401 
The compounds selected for investigation in this study included: atenolol, EE2, 403 
trimethoprim, venlafaxine, carbamazepine, glyburide, and erythromycin (the compound selection 404 
process and additional information about each compound is provided in Section 1.2 of the 405 
Supporting Information). Batch reactor experiments were initiated after the 14-hour regrowth 406 
period by pelleting the biomass via centrifugation and transferring the re-suspended dilution 407 
cultures into 500 mL bottles containing SSM and pharmaceuticals at a target initial concentration 408 
of 10 µg/L each. The bottles were prepared by first drying methanol stocks containing a mixture 409 
of the compounds. Once dry, the pharmaceuticals were resuspended in SSM by stirring for one 410 
hour. At each dilution level (10-2, 10-4, 10-7) triplicate batch reactors with a 350 mL starting 411 
volume were prepared. A control batch reactor was also prepared with a mixture of the biomass 412 
from each dilution level inactivated with sodium azide (0.2 % w/v) (Kim et al., 2005). Every 24 413 
hours, an additional 2 mL of 100 g/L sodium azide stock solution was added to the control batch 414 
reactor to maintain abiotic conditions. Beginning and endpoint 20-mL samples were collected 415 
from each batch reactor corresponding to time points of 30 minutes and 4 days after initiation, 416 
respectively, for pharmaceutical quantification. After collection, samples were spiked with 417 
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deuterated analogs of the target compounds to achieve a target concentration of 2.5  µg/L each, 418 
filtered through a 0.3 µm glass fiber filter (Sterlitech, Kent, WA), and stored at 4°C until analysis 419 
(less than 24h after collection). 10 mL samples were collected at time points of approximately 30 420 
min, 4h, 8h, 12h, 24h, and 48h and filtered through 0.3 µm glass fiber filter (Sterlitech) to 421 
determine dissolved organic carbon concentrations (TOC Analyzer, Shimadzu, Kyoto, Japan). 422 
Total and volatile suspended solids (TSS/VSS) concentrations were determined according to 423 
Standard Methods (2005) at the beginning and end of the experiment (96 hours) for each batch 424 
reactor (Table S5). The average volatile suspended solids concentration between the beginning 425 
and endpoint was used to normalize all carbon oxidation rate and pharmaceutical transformation 426 
extent data (calculation details are provided in Section 2.2 of the Supporting Information). 427 
Transformation extents were also normalized by the amount of time elapsed between the initial 428 
and final sample collections. 429 
Pharmaceutical concentrations were determined via on-line pre-concentration followed 430 
by high performance liquid chromatography and high resolution mass spectrometry (details in 431 
Section 1.3 of the Supporting Information). Background concentrations of pharmaceuticals were 432 
considered negligible as compared to the spiked concentrations based on reported values in 433 
wastewater influents (e.g. Joss et al., 2005; Nakada et al., 2006) and previous characterization of 434 
Ann Arbor WWTP influent (Stadler et al., 2014). Quantification was performed using a matrix-435 
matched calibration curve (Figure S1). Pharmaceutical biotransformation extents and percent 436 
loss for each compound were calculated based on the change between the initial and final 437 
samples.  438 
DNA and RNA sample collection, library preparation, and sequencing 439 
Duplicate 15 mL samples from each batch reactor were collected for DNA analysis from 440 
each of the triplicate dilution cultures between 4h20min and 5h40min after initiating the batch 441 
experiments. The biomass was pelleted via centrifugation at 4°C and 6,200 x g for 5 minutes, the 442 
supernatant was discarded, and the pellet was stored at -80°C until DNA extraction. Duplicate 15 443 
mL samples were collected for RNA analysis from each of the triplicate dilution cultures 444 
between 5h30min and 7h50min after initiating the batch experiments to get a representative 445 
sample of microbial activity at a time when residual organic carbon and pharmaceutical 446 
concentrations were detectable. The biomass was pelleted via centrifugation at 4°C and 6,200 x g 447 
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for 5 minutes, the supernatant was discarded, and the pellet was re-suspended in 2 mL of 448 
RNALater (Qiagen, Valencia, CA) and stored at -80°C until RNA extraction. 449 
DNA and RNA extraction were performed as described in the Supporting Information 450 
(Section 1.4). Amplicon sequencing of the 16S rRNA gene and cDNA were performed on 451 
Illumina MiSeq (Illumina Inc., San Diego, CA) using universal primers F515 (5’- 452 
GTGCCAGCMGCCGCGGTAA-3’) and R806 (5’- GGACTACHVGGGTWTCTAAT-3’) for 453 
bacteria and archaea targeting the V4 region of the 16S rRNA gene (Kozich et al., 2013).  DNA 454 
samples were prepared for shotgun metagenomic sequencing at the University of Michigan DNA 455 
Sequencing Core (details provided in Section 1.5 of the Supporting Information) and sequenced 456 
on a 100-cycle paired end run on a HiSeq 2500 (Illumina). RNA samples were prepared for 457 
shotgun metatranscriptomic sequencing by first enriching the mRNA from the total RNA 458 
extracts using the MICROBExpress Bacterial mRNA Enrichment Kit (Invitrogen, Carlsbad, CA) 459 
based on previous studies (He et al., 2010; Mettel et al., 2010). Individual libraries were 460 
prepared for each sample as for the DNA samples and the samples were multiplexed using 461 
sample-specific adaptors on a single lane of a HiSeq Flow Cell (Illumina).  Sequencing analysis 462 
procedures, parameters, and subsampling depths are provided in Section 1.6 of the Supporting 463 
Information. 464 
Statistical analyses 465 
 Differences in pharmaceutical biotransformation extents and taxonomic and functional 466 
diversity measurements between the dilution conditions were tested with ANOVA. In addition, 467 
post-hoc analysis using two-sided t tests were used to perform pairwise tests of 468 
biotransformation extents and pairwise tests of taxonomic and functional diversity measurements 469 
between the different dilution conditions. Bonferroni corrections were used to account for 470 
multiple comparisons in the post-hoc analyses (Abdi, 2007). We also assessed associations 471 
between the collective extents of pharmaceutical biotransformation and biodiversity by scaling 472 
each compound’s normalized extent of loss (mean of 0, standard deviation of 1) (Zavaleta et al., 473 
2010). Two-sided Spearman rank correlation was used to test associations between biodiversity 474 
measurements and pharmaceutical biotransformation extents. Metatranscriptomic mapped reads 475 
were analyzed using the Bioconductor DESeq2 package based on the negative binomial model 476 
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(Love et al., 2014). More information about the statistical analysis used is given in the 477 
Supplementary Information (Section 1.7).  478 
Experimental Data 479 
Raw metagenomic and metatranscriptomic reads are publically available via MG-RAST (project 480 
ID 12795). Raw 16S rRNA gene and transcript data is publically available via NCBI (project ID 481 
PRJNA319442). Assembled metagenomes are available via the Joint Genome Institute (Taxon 482 
Object ID 3300005080). 483 
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Table and Figure Legends 608 
Table 1. Biodiversity indices based on 16S rRNA gene, 16S rRNA, metagenomic, and 609 
metatranscriptomic sequencing of biomass from the dilution cultures. The same letter indicates 610 
treatments without significant differences based on pairwise comparisons (t test, Bonferroni-611 
adjusted two-sided P>0.05). Reported values are averages and standard deviations of triplicate 612 
batches. 613 
Table 2. Phylogenetic assignments of OTUs with relative activities that significantly associated 614 
with pharmaceutical biotransformation extents. 615 
Figure 1. Rarefaction plots for the dilution cultures based on 16S rRNA gene and 16S rRNA 616 
sequencing (taxonomic) and metagenomic and metatranscriptomic sequencing (functional). 617 
Dilution conditions are shown in black (10-2), dark grey, dotted (10-4) and light grey, dashed (10-618 
7
Figure 2. Average pharmaceutical loss (disappearance of the parent compound, n=3) normalized 620 
to volatile suspended solids concentration for each dilution condition (black: 10
). 619 
-2; dark grey 621 
hatch: 10-4; light grey: 10-7
Figure 3. Relationship between richness and pharmaceutical biotransformation extent. Left (A) 626 
represents the functional richness, and right (B) represents taxonomic richness. Each diamond or 627 
circle represents a different pharmaceutical compound. Open diamonds and circles represent 628 
DNA-based richness and filled diamonds and circles represent RNA-based richness. The 10
). The asterisk (*) by the compound name indicates a significant 622 
difference among the group means (ANOVA, P<0.05). The same letters above the bars indicate 623 
treatments without significant differences between biotransformation extent (t test, Bonferroni-624 
adjusted two-sided P>0.05). Error bars represent standard deviations of triplicate batches.  625 
-629 
7dilution condition (least diverse) is represented in light grey, the 10-4 condition is in grey, and 630 
the 10-2 condition (most diverse) is in black. The average transformation extents across all 631 
compounds are shown with a black line (DNA-based richness) and a cross (RNA-based 632 
richness). Reported P-values and ρ (rho) values (Spearman rank correlation coefficients) are 633 
based on a two-sided Spearman rank correlation test.  634 Au
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Table 1. Biodiversity indices based on 16S rRNA gene, 16S rRNA, metagenomic, and 
metatranscriptomic sequencing of biomass from the dilution cultures. The same letter indicates 
treatments without significant differences based on pairwise comparisons (t test, Bonferroni-
adjusted two-sided P>0.05). Reported values are averages and standard deviations of triplicate 
batches. 
 
Biodiversity index Dilution condition 
10-2 10-4 10-7 
DNA    
Taxonomic richness (unique OTUs) 311  63.0A 123   6.66B 51.0  20.8C 
Chao1 extrapolated taxonomic richness 358  67.8A 136  3.75B 64.1  23.4C 
Shannon taxonomic diversity 2.67   0.189A 2.02   0.0619B 1.37  0.0594C 
Pielou taxonomic evenness  1.05  0.0547A 0.944  0.0239A,B 0.773  0.0902B 
Functional richness (unique functional genes) 4600   45.0A 4560   27.0A 4130  221A 
Chao1 extrapolated functional richness 4760   12.9A 4720   46.9A 4240  181B 
Shannon functional diversity 7.64   0.0103A 7.60   0.00258B 7.55  0.00905C 
Pielou functional evenness 2.08  0.00332A 2.07  0.00308A 2.08  0.00823A 
RNA    
Taxonomic richness (unique OTUs) 512  9.54A 190  21.7B 109  35.9B 
Chao1 extrapolated taxonomic richness 983  61.9A 354  31.7B 208  84.4B 
Shannon taxonomic diversity 2.71  0.0407A 1.95  0.0406B 1.62  0.122C 
Pielou taxonomic evenness 0.906  0.0211A 0.767  0.00654B 0.710  0.102A,B 
Functional richness (unique functional genes) 3930  20.3A 3820  20.1B 3420  106C 
Chao1 extrapolated functional richness 4220  24.1A 4140  53.6A 3650  115B 
Shannon functional diversity 6.51  0.0590A 6.56  0.120A 6.53  0.0369A 
Pielou functional evenness 1.80  0.0175A 1.82  0.0310A  1.83  0.00627A 
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Table 2. Phylogenetic assignments of OTUs with relative activities that significantly associated with pharmaceutical 
biotransformation extents. 
 
Phylum Class Order Family Genus Compound(s) Literature 
supporting role in 
biotransformation 
Proteobacteria Betaproteobacteria Neisseriales Neisseriaceae Vogesella atenolol, 
venlafaxine, 
collective 
Pérez-Pantoja et al., 
2010; Arroyo-
Caraballo and Colon-
Burgos, 2000 
Bacteroidetes Flavobacteriia Flavobacteriales Weeksellaceae Cloacibacterium atenolol, 
collective 
Amorim et al., 2013; 
Allen et al., 2006 
Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae Acidovorax atenolol, 
venlafaxine 
Martínková and Křen, 
2010 
Bacteroidetes Flavobacteriia Flavobacteriales Weeksellaceae Chryseobacterium atenolol, 
venlafaxine 
Helbling et al., 2015; 
Jobanputra et al., 
2011; Takenaka et al., 
2013 
Bacteroidetes Flavobacteriia Flavobacteriales Flavobacteriaceae Flavobacterium atenolol, 
venlafaxine, 
collective 
Crawford and Mohn, 
1985; Tweel et al., 
1988 
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